Print

Repros Therapeutics Inc. (RPRX) Reports Core 1-Year DEXA Study Fully Enrolled Ahead of Schedule and Provides Update for Androxal® Clinical Program  
1/7/2013 9:52:27 AM

THE WOODLANDS, Texas, Jan. 7, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today provided a clinical update of its Androxal® Phase 3 program.
//-->